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ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) was first 
identified in 2012 as a novel etiological agent of severe respiratory disease in hu-
mans. As during infection by other viruses, host sensing of viral double-stranded 
RNA (dsRNA) induces several antiviral pathways. These include interferon (IFN), oli-
goadenylate synthetase (OAS)-RNase L, and protein kinase R (PKR). Coronaviruses, in-
cluding MERS-CoV, potently suppress the activation of these pathways, inducing 
only modest host responses. Our study describes the functions of two accessory pro-
teins unique to MERS-CoV and related viruses, NS4a and NS4b, during infection in 
human airway epithelium-derived A549 cells. NS4a has been previously characterized 
as a dsRNA binding protein, while NS4b is a 2=,5=-phosphodiesterase with structural 
and enzymatic similarity to NS2 encoded by mouse hepatitis virus (MHV). We found 
that deletion of NS4a results in increased interferon lambda (IFNL1) expression, as 
does mutation of either the catalytic site or nuclear localization sequence of NS4b. 
All of the mutant viruses we tested exhibited slight decreases in replication. We 
previously reported that, like MHV NS2, NS4b antagonizes OAS-RNase L, but sup-
pression of IFN is a previously unidentified function for viral phosphodiesterases. 
Unexpectedly, deletion of NS4a does not result in robust activation of the PKR or 
OAS-RNase L pathways. Therefore, MERS-CoV likely encodes other proteins that 
contribute to suppression or evasion of these antiviral innate immune pathways 
that should be an important focus of future work. This study provides additional 
insight into the complex interactions between MERS-CoV and the host immune 
response.
IMPORTANCE Middle East respiratory syndrome coronavirus (MERS-CoV) is the 
second novel zoonotic coronavirus to emerge in the 21st century and cause out-
breaks of severe respiratory disease. More than 2,200 cases and 800 deaths have 
been reported to date, yet there are no licensed vaccines or treatments. Corona-
viruses encode unique accessory proteins that are not required for replication 
but most likely play roles in immune antagonism and/or pathogenesis. Our study 
describes the functions of MERS-CoV accessory proteins NS4a and NS4b during 
infection of a human airway-derived cell line. Loss of these accessory proteins 
during MERS-CoV infection leads to host antiviral activation and modestly atten-
uates replication. In the case of both NS4a and NS4b, we have identified roles 
during infection not previously described, yet the lack of robust activation sug-
gests much remains to be learned about the interactions between MERS-CoV 
and the infected host.
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Middle East respiratory syndrome coronavirus (MERS-CoV) is a recently emerged,highly pathogenic coronavirus first identified in the Middle East in 2012 (1, 2).
Following the 2002 to 2003 severe acute respiratory syndrome (SARS)-CoV pandemic, 
MERS-CoV is the second zoonotic coronavirus discovered in the 21st century. Although 
cases have been largely concentrated on the Arabian Peninsula, a large travel-
associated outbreak in South Korea in 2015 highlights that MERS-CoV remains a global 
concern. MERS-CoV circulates in dromedary camels in Africa and the Middle East, 
having established a reservoir in camels, while closely related viruses are found in 
African bats, suggesting a bat origin for MERS-CoV or its direct ancestors (3–8).
Like all coronaviruses, MERS-CoV has a large positive-sense single-stranded RNA 
(ssRNA) genome of 30,119 nucleotides in length. The 5= two-thirds of the genome 
encodes the functionally conserved replicase proteins, while a core set of structural 
proteins are encoded by all viruses of the Betacoronavirus genus in the 3= 10 kb. 
Additionally found in the 3= end of the genome are accessory genes specific to each 
Betacoronavirus subgenus, interspersed with structural genes. The MERS-CoV accessory 
genes are found only in other betacoronaviruses of the subgenus Merbecovirus (for-
merly lineage C), while betacoronaviruses of other subgenera such as mouse hepatitis 
virus (MHV) (Embecovirus [lineage A]) and SARS-CoV (Sarbecovirus [lineage B]) carry 
unique accessory genes.
Several accessory proteins encoded by MHV and SARS-CoV have been identified as 
antagonists of the innate immune response (9), as have some MERS-CoV accessory 
proteins (10–14). Several studies utilizing ectopically expressed protein and reporter 
systems have identified NS4a, NS4b, and NS5 as putative interferon (IFN) antagonists, 
but these studies may not faithfully recapitulate the complex interactions between viral 
and host factors present during infection (11, 13, 15–17). More recent studies utilizing 
recombinant MERS-CoV have more completely elucidated the functions of some of 
these proteins, but conflicted with early reporter studies. NS4a, a double-stranded RNA 
(dsRNA) binding protein, prevents the generation of protein kinase R (PKR)-induced 
stress granules in some cell types (18). We reported previously that NS4b is a homolog 
of the NS2 protein of MHV and closely related betacoronaviruses of the subgenus 
Embecovirus (formerly lineage A), has 2=,5=-phosphodiesterase (PDE) activity, and acts as 
an antagonist of the oligoadenylate synthetase (OAS)-RNase L pathway (19). In contrast 
to the Embecovirus PDEs, NS4b has an N-terminal nuclear localization signal (NLS) and 
is localized primarily to the nucleus of infected cells (16, 19). NS4b has also been 
reported to antagonize NF-B nuclear translocation during MERS-CoV (12, 14, 18, 19), 
as has NS5 (10).
Building on our previous study characterizing NS4b as an OAS-RNase L antagonist 
(19), we have used recombinant MERS-CoV to further elucidate the roles of NS4a and 
NS4b during infection of human airway epithelium-derived A549 cells (20). Consistent 
with earlier studies, NS4a prevents phosphorylation of PKR and the induction of IFN and 
interferon-stimulated gene (ISG) expression. However, PKR activation in the absence of 
NS4a does not result in phosphorylation of eIF2 (eukaryotic initiation factor 2) or  
translation arrest in A549 cells, in contrast to recent findings in a different cell type (18). 
Unlike other viral dsRNA binding proteins such as vaccinia virus E3L (21) and influenza 
virus NS1 (22), NS4a does not play a significant role in OAS-RNase L antagonism during 
MERS-CoV infection, as deletion of NS4a does not result in RNase L activation or 
enhance RNase L activation in the context of MERS-CoV encoding catalytically inactive 
NS4b.
Our studies of NS4b reveal that in addition to antagonizing OAS-RNase L and 
preventing NF-B activation, NS4b antagonizes IFNL1 expression, with this function 
dependent on both its catalytic activity and nuclear localization and independent of its 
interaction with the OAS-RNase L pathway. This is a unique role for virus-encoded 
phosphodiesterases, which otherwise lack an NLS and act solely as OAS-RNase L 
antagonists (12, 23–26). Together, the results demonstrate that NS4a and NS4b mediate 
both expected and unexpected functions during MERS-CoV infection and further 
demonstrate the importance of studying the function of these proteins in the context
FIG 1 MERS-CoV NS4a and NS4b recombinant mutants. (A) MERS-CoV genome RNA with open reading 
frames shown. (B) NS4a and NS4b proteins expressed by wild-type and mutant MERS-CoVs. The catalytic 
His residues of the PDE are shown, and the vertical black bar indicates the NLS of NS4b; the red lettering 
indicates amino acid substitutions of the catalytic His residue and within the NLS. (C) Expression of viral 
proteins from recombinant MERS-CoV viruses. A549DPP4 cells were infected at an MOI of 10 with WT 
MERS-CoV, MERS-ΔNS4a, MERS-ΔNS4ab, MERS-NS4bH182R, or MERS-NS4bNLSmut or mock infected. Cell 
lysates were prepared at 24 and 48 h postinfection, analyzed by SDS-PAGE, and probed by Western 
blotting with rabbit antiserum against NS4a and NS4b or mouse monoclonal antibodies against MERS 
nucleocapsid protein (N) and GAPDH. The Western blot data are from one representative of three 
independent infections.
of infection to uncover the full range of their interactions with the innate immune
response.
RESULTS
Construction and characterization of recombinant NS4a and NS4b MERS-CoV 
mutants. In order to study the effects of NS4a and NS4b on MERS-CoV interactions with
the host innate immune system, we used a panel of recombinant MERS-CoV mutants.
Deletion mutants MERS-ΔNS4a and MERS-ΔNS4ab were generated from the MERS-CoV
infectious clone derived from the MERS-EMC2012 strain (27) as follows and are de-
scribed in detail in Materials and Methods and diagrammed in Fig. 1A and B. Briefly,
MERS-ΔNS4a was generated by altering the start codon (ATG¡ATT) and adding an
in-frame stop codon 10 codons downstream (TGG¡TGA) to ablate synthesis of the
FIG 2 Subcellular localization of MERS-CoV NS4b expression. (A) The nuclear localization signal (NLS) was 
mapped by mutating basic residues in pCAGGS-NS4b, and NS4b was ectopically expressed in A549 cells 
by DNA transfection. Twenty-four hours posttransfection, cells were fixed and stained for NS4b using 
anti-NS4b rabbit serum and goat anti-rabbit AF594 secondary antibody. (B) A549DPP4 cells were infected 
with WT MERS-CoV, MERS-NS4bH182R, or MERS-NS4bNLSmut (MOI  5). Cells were fixed 24 h postinfection 
and stained with anti-NS4b rabbit serum and goat anti-rabbit AF594 secondary antibody. The images 
shown in both panels are representative of at least three fields of cells from three independent 
experiments.
NS4a protein. MERS-ΔNS4ab was generated by engineering a 951-nucleotide deletion 
of open reading frame 4a (ORF4a) and the majority of ORF4b without disrupting the 
transcription regulatory sequence (TRS) of NS5. To verify the loss of NS4b and/or NS4a 
expression by these mutants, human A549 cells stably expressing the MERS-CoV 
receptor DPP4 (A549DPP4) were infected with MERS-CoV mutants at a multiplicity of 
infection (MOI) of 10, and protein lysates were harvested at 24 and 48 h postinfection 
(hpi) to assess protein expression by Western blotting. As expected, NS4a is not 
synthesized during infection with MERS-ΔNS4a, and neither protein is detectable 
during MERS-ΔNS4ab infection (Fig. 1C).
To further investigate the functional domains of NS4b, we utilized two mutant 
viruses with targeted mutations in either the phosphodiesterase domain or the NLS. 
MERS-NS4bH182R encodes NS4b with a catalytically inactive phosphodiesterase domain, 
which was generated from the MERS-CoV infectious clone as previously described (19,
27). The NS4b NLS was previously described as bipartite (RKR11KRR), with the first basic
motif more potently determining nuclear localization (12, 16). However, this first motif 
overlaps with the upstream ORF4a, and so mutation of the RKR motif without causing 
amino acid changes in ORF4a is impossible. To determine how to construct the NS4b 
NLS mutant (NS4bNLSmut), we mapped the nuclear localization signal (NLS) sequence by 
expressing wild-type (WT) and various NLS mutant NS4b genes from a pCAGGS vector 
in A549 cells and detecting NS4b proteins by immunofluorescent staining (Fig. 2A). 
These plasmids expressed NS4b proteins with mutations of the RKR motif, the down-
stream KRR motif, and a previously undescribed basic motif that lies between the two
previously characterized motifs (RKR5KKLR2KRR). All mutant proteins exhibited primarily 
cytoplasmic localization; thus, we engineered mutation of the central (KKLR) and
FIG 3 NS4a colocalizes with dsRNA around replication/transcription complexes (RTC) during MERS-CoV 
infection. A549DPP4 cells were infected with WT MERS-CoV (MOI  5), fixed 24 h postinfection, and 
stained with rabbit anti-NS4a serum, mouse anti-dsRNA J2, and guinea pig anti-nsp8 serum and then 
with secondary antibodies goat anti-rabbit AF647, goat anti-mouse AF488, and goat anti-guinea pig 
AF568. The images shown are representative of at least three fields of cells from three independent 
experiments.
downstream (KRR) motifs into the MERS-CoV infectious clone to generate MERS-
NS4bNLSmut (Fig. 1B), as described in detail in Materials and Methods (27).
While NS4b expressed during MERS-CoV infection is primarily expressed in the 
nucleus, during infection with MERS-NS4bNLSmut, NS4b exhibits predominantly cyto-
plasmic localization, as expected (Fig. 2B). During infection with MERS-NS4bH182R and 
MERS-NS4bNLSmut, slightly less NS4b was synthesized than during wild-type (WT) 
MERS-CoV infection (Fig. 1C), consistent with previous studies of viral PDEs in which 
expression of mutant protein was less robust than expression of wild-type protein (19). 
We consistently detected an extra lower band when probing for NS4b. This will be 
addressed in the Discussion.
NS4a colocalizes with dsRNA around RTCs. Previous studies have shown that 
overexpressed NS4a binds to dsRNA (13, 17). Additionally, NS4a is broadly cytoplasmic 
when overexpressed in uninfected cells, but colocalizes with dsRNA during infection 
(11–13). We infected A549DPP4 cells with MERS-CoV and used immunofluorescent 
microscopy to determine NS4a localization. NS4a exhibits a primarily punctate, peri-
nuclear distribution with some diffuse distribution in the cytoplasm (Fig. 3). Cells were 
costained for NS4a with J2 antibody to detect dsRNA and antiserum against the viral 
primase, nsp8, a component of the viral polymerase complex and therefore a marker for 
virus replication/transcription complexes (RTCs) (28). NS4a colocalizes with dsRNA, and 
both are largely colocalized with nsp8, though dsRNA and NS4a appear more broadly 
distributed (Fig. 3). This may indicate that either some dsRNA and NS4a localized 
outside the RTC or the sensitivity of the assay is insufficient to detect all of the nsp8.
NS4a and NS4b deletion mutants are modestly attenuated in A549DPP4 cells. To 
assess the impact of NS4a and NS4b mutation on viral replication, we carried out 
growth curve experiments in Vero and A549DPP4 cells with MERS-ΔNS4a and MERS-
ΔNS4ab. Vero cells lack a type I IFN response and were used to ensure recombinant 
viruses are not inherently replication deficient. We infected both cell types with WT or 
mutant MERS-CoV at an MOI of 1 and harvested supernatant at predetermined times 
postinfection for titration by plaque assay. All viruses replicated with equivalent kinetics 
to WT MERS-CoV and to equal titers in Vero cells, indicating that deletion of NS4a and 
NS4b does not disrupt critical aspects of the viral life cycle (Fig. 4A). In contrast, deletion 
of NS4a and/or NS4b modestly attenuated MERS-CoV replication in A549DPP4 cells at an 
MOI of 1, with the reductions in titer significant at most time points (Fig. 4B and C). 
Deletion of both NS4a and NS4b resulted in a slightly greater attenuation than deletion 
of NS4a alone, though this difference was not statistically significant. That replication of 
these mutant viruses is attenuated in A549DPP4 cells and not in permissive Vero cells 
strongly suggests that the deficiency is linked to the intact antiviral responses in A549 
cells.
NS4a and NS4b modestly suppress IFN expression. Previous studies of NS4a and 
NS4b have conflicted on the role of these proteins in suppressing the IFN response 
(11–14, 15, 18). We aimed to systematically characterize the role of NS4a and NS4b in 
antagonism of IFN induction during MERS-CoV infection. To ensure that our newly 
generated A549DPP4 cells were a suitable platform for investigating MERS-CoV suppres-
sion of the IFN response, we infected them with Sendai virus (SeV), Sindbis virus (SINV),
and WT MERS-CoV. In contrast to SeV and SINV, which robustly induced IFN and ISG
expression by 12 hpi, MERS-CoV induced little IFNL1 or IFNB expression throughout a
36-h course of infection (Fig. 5A and B).
FIG 4 MERS-CoV NS4a and NS4b mutants are attenuated in IFN competent cells. (A) Vero cells were
infected in triplicate at an MOI of 1 with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab. Supernatants
were collected at indicated times postinfection, and infectious virus was quantified by plaque assay. (B)
A549DPP4 cells were infected in triplicate at an MOI of 1 with WT MERS-CoV, MERS-ΔNS4a, and
MERS-ΔNS4ab, and replication was quantified as in panel A. (C) Statistical significance for mutant virus
replication versus WT was calculated by two-way ANOVA. Data are from one representative of three
independent experiments. In panel A, the 72-h postinfection data point was only assessed in one out of
three experiments. Data are displayed as means  standard deviation (SD). *, P  0.05; **, P  0.01; ***,
P  0.001; ****, P  0.0001.
To determine if NS4a and/or NS4b contributes to suppression of IFN expression, we 
infected A549DPP4 cells with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab and at 24 
and 36 h postinfection compared gene expression of IFN and selected ISGs by quan-
titative real-time PCR (qRT-PCR). In contrast to the minimal increases observed during 
WT MERS-CoV infection over mock-infected cells, MERS-ΔNS4a or MERS-ΔNS4ab infec-
tion resulted in significantly elevated levels of IFNL1 mRNA and representative ISG OAS2 
and IFIT2 mRNAs. Interestingly there was no significant induction of type I IFN (Fig. 5C). 
We did not observe any significant additive effect on antiviral gene expression from the 
additional deletion of NS4b. However, deletion of ORF4a and/or -b (Fig. 5C) did not 
result in IFN induction approaching the levels we observed in response to SeV and SINV 
infection (Fig. 5B), suggesting MERS-CoV encodes additional, potent IFN antagonists 
and/or utilizes other mechanisms such as sequestration of dsRNA in membrane-bound 
RTCs to avoid sensing by antiviral receptors.
NS4b is a novel IFN antagonist. We previously reported that MERS-CoV NS4b is a 
member of the 2H-phosphoesterase superfamily of proteins and antagonizes OAS-
RNase L activation during MERS-CoV infection through its 2=,5=-PDE activity (19, 29). 
Unlike previously studied viral PDEs such as mouse hepatitis virus (MHV) NS2, the 
torovirus pp1a C-terminal domain, and the rotavirus VP3 C-terminal domain, which 
exhibit primarily cytoplasmic localization (23, 24), NS4b localizes primarily to the 
nucleus (Fig. 2B), suggesting additional functions. Earlier studies suggested that NS4b 
nuclear localization might be important for suppressing IFN expression (15), but no 
previous studies have specifically addressed the role of its catalytic activity in IFN 
antagonism (30). To characterize the function of the NS4b PDE domain and NLS, we 
used recombinant MERS-NS4bH182R and MERS-NS4bNLSmut. In Vero cells, both mutant 
viruses replicated with equivalent kinetics to WT MERS-CoV and to equal titers (Fig. 6A). 
In A549DPP4 cells, both viruses are modestly and similarly attenuated at late time points
FIG 5 NS4a and NS4b antagonize IFN expression. (A) A549DPP4 cells were mock infected or infected in 
triplicate with WT MERS-CoV at an MOI of 5. RNA was harvested, and gene expression was quantified by 
qRT-PCR and expressed as fold change over mock infected using the 2Δ(ΔCT) formula. (B) A549DPP4 cells 
were infected in triplicate with SeV or SINV at an MOI of 5, and at 12 h postinfection, expression of the 
indicated genes in infected/mock-infected cells was calculated as in panel A. (C) A549DPP4 cells were 
mock infected or infected in triplicate with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab at an MOI of 
5 and RNA was harvested at the indicated times postinfection. IFNL1, IFNB, OAS2, and IFIT2 mRNA levels 
were quantified by qRT-PCR and calculated over mock-infected cells as in panel A. Data are from one 
representative of three independent experiments and are displayed as means  standard errors of the 
mean (SEM). Statistical significance was calculated by unpaired Student’s t test: *, P  0.05; **, P  0.01; 
***, P  0.001; ****, P  0.0001.
at an MOI of 1, and throughout the course of infection at an MOI of 0.1 where two out
of three independent experiments yielded significant differences (Fig. 6B and C).
qRT-PCR analysis demonstrated that mutation of either the catalytic site or NLS results
in significantly increased IFN and ISG expression during MERS-CoV infection (Fig. 6D).
To further investigate whether PDE-dependent IFN antagonism is unique to MERS-
CoV NS4b, we infected A549 cells stably expressing the MHV receptor CEACAM-1
(A549mCEACAM-1) with WT MHV or MHV encoding catalytically inactive NS2 (MHV-
NS2H126R), its native PDE. Both viruses induced slightly more IFNL1 expression than we
observed for MERS-CoV, but MHV-NS2H126R did so to an identical degree as WT MHV 
(Fig. 6E), demonstrating that the MHV PDE does not antagonize IFN induction in this
cell type, consistent with our previous observation in murine cells (31).
Finally, to confirm that NS4b antagonism of IFN expression is a novel viral PDE 
function and uncoupled from its interaction with the OAS-RNase L pathway, we
assessed immune activation by MERS-CoV and NS4b mutants in A549DPP4 cells ablated 
of RNase L expression by CRISPR-Cas9 (i.e., clustered regularly interspaced short palin-
dromic repeats with Cas9) as previously described (32). Both MERS-NS4bH182R and
MERS-NS4bNLSmut induced greater IFNL1, OAS2, and IFIT2 expression than WT MERS-CoV 
(Fig. 7A) in RNase L knockout (KO) cells, recapitulating the results we observed in
wild-type A549DPP4 cells. To confirm that these cells were indeed unable to activate 
RNase L, cells were infected with SINV, a known potent activator of OAS-RNase L
(32), and rRNA integrity was analyzed by Bioanalyzer (Fig. 7B), as previously
described (19, 23).
NS4a does not contribute to OAS-RNase L antagonism during MERS-CoV in-
fection. dsRNA binding proteins encoded by viruses such as vaccinia virus (E3L) and
FIG 6 MERS-CoV NS4b NLS and PDE catalytic mutants are attenuated in A549 cells and exhibit increased 
type III IFN expression. (A) Vero cells were infected in triplicate at an MOI of 1 with WT MERS-CoV, 
MERS-ΔNS4a, and MERS-ΔNS4ab. Supernatants were collected at indicated times postinfection and 
infectious virus quantified by plaque assay. (B) A549DPP4 cells were infected in triplicate at an MOI of 1 
or 0.1 with WT MERS-CoV, MERS-ΔNS4a, and MERS-ΔNS4ab, and replication was quantified as in panel A. 
Data are from one representative of three independent experiments and are displayed as means  
standard deviation (SD). (C) Statistical significance for mutant virus replication versus WT was determined 
by two-way ANOVA: *, P  0.05; **, P  0.01, ***, P  0.001; ****, P  0.0001. (D) A549DPP4 cells were mock 
infected or infected in triplicate at an MOI of 5 with WT MERS-CoV, MERS-NS4bNLS, and MERS-NS4bH182R, 
and RNA was harvested at the indicated times postinfection. Gene expression over mock-infected cells 
was measured by RT-qPCR and calculated over mock-infected cells using the 2Δ(ΔCT) formula. Data are 
from one representative of three independent experiments and expressed as mean  SEM. Statistical 
significance was determined by unpaired Student’s t test: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  
0.0001. (E) A549mCEACAM-1 cells were mock treated or infected with WT MHV or MHV-NS2H126R at an MOI 
of 5, and RNA was harvested at 6 and 12 h postinfection. IFNL1 expression was determined as in panel 
D. Data are from one representative experiment of three.
influenza A virus (NS1) antagonize activation of the antiviral OAS-RNase L pathway,
presumably by sequestration of viral RNA (21, 22, 33). Since RNase L activation by
MERS-NS4bH182R is less robust than by other viruses such as SINV in A549DPP4 cells
(Fig. 7), we hypothesized that NS4a may contribute to antagonism of this pathway
during MERS-CoV infection. To test this hypothesis, we infected A549DPP4 cells at an
MOI of 5, harvested RNA 48 h postinfection, and assessed rRNA degradation using a
Bioanalyzer (19, 23). We included SINV as a control for robust RNase L activation (32).
RNase L activation is inferred from RNA degradation depicted by the banding pattern
in the pseudogel image. MERS-NS4bH182R and MERS-ΔNS4ab induced more rRNA
degradation than WT MERS-CoV, indicating activation of RNase L (Fig. 8). Infection with
MERS-NS4bNLSmut also did not result in increased rRNA degradation, as expected given
previous work demonstrating cytoplasmic PDE localization mediates RNase L antago-
FIG 7 NS4b antagonizes IFN expression independently of RNase L activation. (A) RNase L KO A549DPP4
cells were mock infected or infected in triplicate at an MOI of 5 with MERS-CoV, MERS-NS4bNLS, and
MERS-NS4bH182R. RNA was harvested at the indicated times postinfection, mRNA levels expression was
quantified by qRT-PCR in and expression in infected/mock-infected cells calculated using the 2Δ(ΔCT)
formula. Data are from one representative experiment of three, expressed as mean  SEM, and statistical
significance was determined by unpaired Student’s t test: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P 
0.0001. (B) A549DPP4 and RNase L (RL) KO A549DPP4 cells were mock treated or infected with SINV at an
MOI of 1 with SINV, and RNA was harvested at 24 h postinfection. RNA was assessed for rRNA degradation
using an Agilent Bioanalyzer. The positions of 28S and 18S rRNA are indicated.
FIG 8 Loss of NS4a does not activate RNase L during MERS-CoV infection. A549DPP4 cells were mock 
infected or infected with WT MERS-CoV, MERS-ΔNS4a, MERS-ΔNS4ab, MERS-NS4bH182R, MERS-NS4bNLSmut 
(MOI  5), or SINV (MOI  1). RNA was harvested at 48 h postinfection for MERS-CoV infection and at 24 
h postinfection for SINV infection and assessed for rRNA degradation by Agilent Bioanalyzer. 28S and 18S 
rRNA positions are indicated. Data are from one representative of four independent experiments.
nism (34). However, infection with MERS-ΔNS4a also did not induce increased rRNA 
degradation relative to WT MERS-CoV, indicating that the absence of NS4a alone is not 
enough to activate RNase L in this cell type (Fig. 8). Infection with MERS-ΔNS4ab did not 
induce more robust rRNA degradation than MERS-NS4bH182R, suggesting that NS4a 
does not play a significant role in antagonism of RNase L during MERS-CoV infection. 
This result demonstrates that NS4a has both functional similarities to and differences 
from other viral dsRNA binding proteins.
NS4a antagonizes PKR activation, but not protein synthesis, during MERS-CoV 
infection. A recent study showed that loss of NS4a during infection led to PKR 
activation, translational arrest, and stress granule formation, but only in certain cell 
types (18). We investigated whether NS4a antagonizes the dsRNA binding antiviral 
effector protein kinase R (PKR) during MERS-CoV infection in A549DPP4 cells. A549DPP4 
cells were infected with WT MERS-CoV and MERS-ΔNS4a at an MOI of 3, lysed at 24 h 
postinfection and analyzed for PKR activation by Western blotting. MERS-ΔNS4a, but 
not WT MERS-CoV, induced PKR phosphorylation (Fig. 9A). PKR phosphorylation during 
MERS-ΔNS4a infection was also observed at 16 and 48 h postinfection (data not shown). 
However, despite the activation of PKR, we did not detect phosphorylation of eIF2 
above background levels, suggesting that activation of PKR by MERS-ΔNS4a in 
A549DPP4 cells is not sufficient to engage downstream elements of this pathway or that 
MERS-CoV encodes an additional antagonist that blocks steps downstream of PKR 
phosphorylation. In contrast, SINV infection promotes robust phosphorylation of PKR 
and eIF2 in the same cells, indicating the lack of eIF2 phosphorylation during 
MERS-ΔNS4a is not due to a deficiency of this pathway in A549DPP4 cells (Fig. 9A).
Although we did not detect eIF2 phosphorylation by immunoblotting, we wanted 
to confirm that PKR activation during MERS-ΔNS4a infection does not mediate trans-
lation arrest in A549DPP4 cells. Thus, we compared protein synthesis during infection 
with MERS-ΔNS4a and WT MERS-CoV. We either mock infected or infected A549DPP4 
cells with WT MERS-CoV or MERS-ΔNS4a. We treated cells 18 and 24 h postinfection 
with puromycin for 10 min to label nascent proteins prior to protein harvest. We used 
immunoblotting with an antipuromycin antibody to specifically detect newly synthe-
sized proteins and used Coomassie staining to assess total protein levels (35). Decrease 
in puromycin signal indicates translation arrest. Puromycin signal was not lower in 
MERS-ΔNS4a-infected A549DPP4 cells compared to WT MERS-CoV, indicating PKR phos-
phorylation did not induce downstream translation arrest (Fig. 9B).
In contrast to A549DPP4 cells, we observe no phosphorylation of PKR during MERS-
ΔNS4a infection in 293TDPP4 cells (Fig. 9C). Furthermore, MERS-CoV shut down protein 
synthesis during infection of these cells as previously reported with no enhancement of 
translation arrest from deletion of NS4a (36) (Fig. 9D). This confirms the observed loss 
of protein synthesis occurs by an NS4a-independent mechanism and highlights that 
differences in cell type may affect levels of activation of the dsRNA-induced innate 
immune pathways.
DISCUSSION
Studies from other labs as well as data presented herein have demonstrated that 
MERS-CoV only modestly induces three major antiviral pathways: IFN production and 
signaling, OAS-RNase L, and PKR. This is likely due largely to viral antagonists of 
dsRNA-induced host responses. Our study, as well as recent reports from other labs, has 
shown that deletion of MERS-CoV accessory proteins from recombinant viruses leads to 
enhanced activation of antiviral pathways. However, these effects are relatively small 
compared to those in other RNA viruses, and deletion of these accessory proteins only 
mildly attenuates replication. This is in contrast to early studies utilizing overexpression 
and reporter plasmids or ectopic expression from heterologous virus showing robust 
suppression of IFNB induction by NS4a and NS4b (11, 13–16). Thus, caution is warranted 
in extrapolating from studies that rely only on ectopic expression.
We have used recombinant MERS-CoV mutants to study interactions between the 
accessory proteins NS4a and NS4b and the host immune response. All of the viruses
FIG 9 Loss of NS4a activates PKR but does not lead to eIF2 phosphorylation or translation arrest in 
A549DPP4. A549DPP4 cells were mock infected or infected with WT MERS-CoV and MERS-ΔNS4a (MOI  3) 
or SINV (MOI  1). (A) Cell lysates were harvested at 24 h postinfection, and proteins were separated by 
SDS-PAGE and immunoblotted with antibodies against phosphorylated PKR (p-PKR), PKR, phosphory-
lated eIF2 (p-eIF2), eIF2, MERS-CoV N, and GAPDH. (B) Prior to cell lysate harvest, at 18 and 24 h 
postinfection, cells were treated with puromycin (10 g/ml) for 10 min. Proteins were separated by 
SDS-PAGE and analyzed either by immunoblotting with antibodies against puromycin, MERS N protein, 
or GAPDH or Coomassie stain for labeling of total proteins. (C) 293TDPP4 cells were infected and cell 
lysates harvested as in panel A. (D) 293TDPP4 cells were infected and cell lysates harvested as in panel B. 
Data are from one representative of four (A), three (B), or two (C and D) independent experiments.
with mutations or deletions in NS4a and NS4b were modestly attenuated compared to
WT MERS-CoV in A549DPP4 cells. These modest differences are consistent with previous
studies of MERS-CoV accessory proteins (10, 12, 14, 18, 30). Furthermore, there is a
clinical report of human isolates with a 16-amino-acid deletion in NS4a (37) and West
African camel MERS-CoV isolates with ORF3 and ORF4b deletions, likely due to founder
effects upon introduction into these populations (30). The isolation of these viruses 
supports findings that MERS-CoV accessory proteins are not definitive determinants of 
viral replication. However, all other known circulating MERS-CoV isolates and MERS-
CoV-like viruses carry intact accessory ORFs, strongly suggesting that these proteins do 
play important roles in promoting viral fitness.
We found roles for both NS4a and NS4b in suppressing IFNL1 expression in response 
to MERS-CoV infection, which is notably muted compared to that in other RNA viruses
(Fig. 5 and 6). The lack of a similar increase in IFNB expression in response to mutant 
MERS-CoV infection is likely due to generally less robust expression of IFNB in A549
cells, which preferentially express IFNL1 like other epithelial cells derived from barrier 
surfaces (38). We found that NS4b IFN antagonism was dependent on nuclear local-
ization, confirming an earlier report (15), and its catalytic activity.
NS4b is the first viral phosphodiesterase known to suppress antiviral pathways in 
addition to RNase L, distinguishing it from phosphodiesterases found in the genomes 
of other coronavirus subgenera (Fig. 6). While the exact mechanism of NS4b IFN 
antagonism remains unclear, several host-encoded PDEs within the same protein family 
are known or believed to participate in various steps of RNA processing (29, 39). 
Whether, like some cellular PDEs (40), NS4b can cleave 3=-5=-linked phosphodiester 
bonds in addition to 2=-5= oligoadenylates and whether it mediates any of its immune 
antagonist functions through directly or indirectly acting on host RNAs is an ongoing 
area of study. Finally, our data demonstrate that NS4b antagonism of IFN is distinct 
from its RNase L antagonist activity (Fig. 7), demonstrating that NS4b has at least two 
independent functions.
We observed reduced expression of mutant NS4b compared to WT protein, as we 
reported previously (19). It is not known whether this reduced expression is due to 
reduced protein stability or to the antibody not recognizing the mutant protein as 
efficiently as the WT protein. However, the abundance of NS4b during infection with 
MERS-NS4bNLSmut, though lower than that of WT protein, is sufficient to fully prevent 
RNase L activation, indicating mutation does not reduce NS4b levels below an effective 
concentration (23, 34, 41) (Fig. 7). Thus, it is unlikely that decreased mutant protein 
abundance is responsible for the observed IFN phenotype (24). We observed a faster-
migrating protein, also staining with antiserum directed against NS4b (Fig. 1C). We 
presume that this faster-migrating protein was not detected in NS4b mutant-infected 
cells due to its lower expression level relative to full-length NS4b and because it is 
weakly expressed even in WT MERS-CoV NS4b cells. We do not know the identity of this 
band. However, we speculate it could be a breakdown product of full-length NS4b or 
more interestingly a protein initiated at one of several ATGs located downstream and 
in frame with the NS4b initiation site.
Activation of RNase L during MERS-NS4bH182R infection is less robust than during 
infection with MHV-NS2H126R in macrophages (23) or SINV infection of A549 cells (32)
(Fig. 7), suggesting MERS-CoV may have redundant mechanisms for inhibiting this 
pathway. Based on the role of the viral dsRNA binding proteins NS1 of influenza virus 
and E3L of vaccinia virus (21, 22, 33) in blocking RNase L activation as well as IFN and 
PKR, we hypothesized that NS4a contributes to antagonism of OAS-RNase L. Surpris-
ingly, infection with MERS-ΔNS4a did not induce increased rRNA degradation com-
pared to wild-type virus, nor did NS4a deletion produce any additive effect on RNase 
L activation in combination with deletion of NS4b. Nevertheless, the lack of robust 
RNase L activation even when NS4b is catalytically inactive suggests the possibility 
MERS-CoV does encode additional antagonists. One intriguing possibility is nsp15; its 
MHV ortholog has recently been described as contributing to evasion of multiple 
dsRNA-sensing pathways (42, 43). Alternatively, as has been speculated for MHV, 
MERS-CoV dsRNA may be contained, even in the absence of NS4a, in viral replication/
transcription complexes (RTCs) and therefore hidden from antiviral sensors (44, 45).
Due to its dsRNA-binding activity, we also hypothesized that NS4a inhibits PKR 
activation. One previous study showed that ectopically expressed NS4a inhibits PKR 
activation and can functionally replace the native PKR antagonist of encephalomyo-
carditis virus (14). Deletion of NS4a within recombinant MERS-CoV has previously been 
shown to result in enhanced translation arrest compared to WT MERS-CoV in HeLa cells 
(18). Consistent with this, we found that deletion of NS4a results in PKR phosphoryla-
tion, but in A549DPP4 cells, this did not lead to phosphorylation of eIF2 above 
background levels, and MERS-ΔNS4a did not induce more translation arrest than WT 
MERS-CoV. In 293TDPP4 cells, MERS-CoV induced translation arrest as previously re-
ported (36), but we did not observe a more robust effect during MERS-ΔNS4a infection. 
Furthermore, PKR was not phosphorylated in 293TDPP4 cells during MERS-ΔNS4a infec-
tion, confirming the PKR-independent mechanism of translational arrest and highlight-
ing differences between cell types in antiviral pathway activation. These differences
demonstrate the importance of using multiple model systems to fully elucidate inter-
actions between viral proteins and host immune pathways.
Despite the lack of robust replication phenotypes, studies of MERS-CoV accessory
proteins from other labs as well as our own have identified novel and important
virus-host interactions that likely contribute in important ways to maintenance of
MERS-CoV in its ecological niche and possibly during infection of the human respiratory
tract. Future work on MERS-CoV accessory proteins in animal models and in vitro
systems that more faithfully recapitulate the human airway should more fully answer
the question of how these proteins contribute to replication under immune pressure
and to pathogenesis.
MATERIALS AND METHODS
Recombinant viruses. Recombinant WT MERS-CoV and mutants were derived from the EMC/2012 
strain cDNA clone, all by introducing mutations into cDNA fragment F assembling the genome fragment 
and recovering infectious virus as described previously (27).
To ablate expression of MERS NS4a, PCR was performed with primers EMCmut4A (5=-NNNNNNTTA 
ATTAACGAACTCTATTGATTACGTGTCTCTGCTTAATCAAATTTGACAGAAGTACCTTAACTC-3=) and MERS: 
F3941 (5=-CACCGAAATGCATGCCAGCC-3=). The positions of the F3941 within the MERS genome are 
28321 to 28302. This product was digested with PacI and NcoI, gel purified, and then ligated into the 
MERS F plasmid, which had been similarly digested.
To remove MERS NS4a and NS4b expression, PCR was performed with primers delta4AB (5=-NNNN 
NNTTAATTAAGTTCATTCTTATCCCATTTTACATC-3=) and MERS:F3415 (5=-GAGGGGGTTTACTATCCTGG-3=). 
This product was digested with PacI and SanDI, gel purified, and then ligated into the MERS F plasmid, 
which had been similarly digested. The delta4AB primer uses the PacI site just upstream of NS4a, and 
then the rest of this primer’s sequence is from positions 26795 to 26819 in the MERS genome. The 
deletion removes nucleotides 25844 to 26794 in the MERS genome and does not disrupt either the 40 
nucleotides upstream of or the transcription regulatory sequence (TRS) of NS5.
MERS-NS4bH182R was previously described (19). MERS-4bNLSmut was constructed by substituting 
alanine for each of residues 31, 33, 36, 37, 38, and 43. Briefly, one PCR product was generated using 
primers MERS:F1376 (5=-GTTTCTGTCGATCTTGAGTC-3=) and MERS4bR (5=-NNNNNNCGTCTCGCAACGTAG 
GCCAGTGCCTTAGTTGGAGAATGGCTCCTC-3=). A second PCR was performed with the primers MERS4bF 
(5=-NNNNNNCGTCTCCGTTGCGGCTGCATTTTCTCTTCTGGCCCATGAAGACCTTAGTGTTATTG-3=) and MERS: 
F3415 (5=-GAGGGGGTTTACTATCCTGG-3=). The positions of the F1376 primer in the context of the MERS 
genome are 25748 to 25767, while the positions for the reverse F3415 primer are 27815 to 27796. The 
products were gel isolated, digested with BsmBI (underlined in the primers shown above), and ligated 
with T4 DNA ligase. The resultant product was digested with PacI and SanDI, gel purified, and then used 
to replace the corresponding region in the MERS F plasmid which had been similarly digested. All 
recombinant viruses were isolated as previously described (27).
Sindbis virus Girdwood (G100) (SINV) was obtained from Mark Heise, University of North Carolina, 
Chapel Hill, and prepared as previously described (46), and Sendai virus (SeV) Cantell strain was obtained 
from Carolina Lopez, University of Pennsylvania, Philadelphia, and prepared as previously described (47).
Cell lines. Vero CCL-81 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) plus 10%
fetal bovine serum (FBS), penicillin-streptomycin, gentamicin, sodium pyruvate, and HEPES. Human A549 
cells were cultured in RPMI 1640 supplemented with 10% FBS and penicillin-streptomycin. A549DPP4 and 
293TDPP4 cells were constructed by lentivirus transduction of DPP4. The plasmid encoding the cDNA of 
DPP4 was purchased from Sino Biological. The cDNA was amplified using forward primer 5=-GACTCTA 
GAATGAAGACACCGTGGAAGGTTCTTC-3= and reverse primer 5=-TCGAGACCGAGGAGAGGGTTAGGGATAG 
GCTTACCAGGTAAAGAGAAACATTGTTTTATG-3=. A V5 tag was introduced to the 3= end of the cDNA by 
PCR to enable easy detection of DPP4. The amplicon was cloned into pCR4-TOPO TA cloning vector 
(Invitrogen K457502), to make pCR4-DDP4-V5. The fragment containing DPP4-V5 was digested by the 
XbaI and SalI restriction enzymes from pCR4-DPP4-V5 and was cloned into pLenti-GFP in place of green 
fluorescent protein (GFP), generating pLenti-DPP4-V5. The resulting plasmids were packaged in lentivi-
ruses pseudotyped with vesicular stomatitis virus glycoprotein G (VSV-G) to establish the gene knock-in 
cells as previously described (32). Forty-eight hours after transduction, cells were subjected to hygro-
mycin (1 mg/ml) selection for 3 days and single-cell cloned. Clones were screened for DPP4 expression 
and susceptibility to MERS-CoV replication. RNase L knockout A549DPP4 cells were generated as previ-
ously described for parental A549 cells (32). A549mCEACAM-1 cells were generated as described above for 
A549DPP4 cells, but by insertion of mouse Ceacam-1 (GenBank accession no. NM_001039185.1) into the 
lentivirus vector rather than human DPP4.
NS4b expression from pCAGGS plasmid. WT NS4b and the indicated mutant NS4b constructs were 
synthesized and purchased from Bio Basic in vector pUC57 flanked by restriction sites ClaI and XhoI. 
pUC57 plasmids were digested and NS4b fragments gel purified for ligation into pCAGGS expression 
vector. Ectopic expression was conducted using Lipofectamine 2000 transfection reagent (Thermo Fisher 
no. 11668027) following the provided protocol. At 24 h posttransfection, cells were fixed and stained as 
described below.
MERS-CoV infections and titration. Viruses were diluted in serum-free RPMI and added to cells for 
absorption for 45 min at 37°C. Cells were washed three times with phosphate-buffered saline (PBS) and 
fed with RPMI plus 2% FBS. One hundred fifty microliters of supernatant was collected at the times 
indicated and stored at 80°C for titration by plaque assay on Vero CCL-81 cells as previously described 
(27). All infections and virus manipulations were conducted in a biosafety level 3 (BSL3) laboratory using 
appropriate personal protective equipment and protocols.
Immunofluorescent staining. At indicated times postinfection, cells were fixed with 4% parafor-
maldehyde for 30 min at room temperature. Cells were then washed three times with PBS and 
permeabilized for 10 min with PBS plus 0.1% Triton X-100. Cells were then blocked in PBS and 2% bovine 
serum albumin (BSA) for 45 to 60 min at room temperature. Primary antibodies were diluted in blocking 
buffer and incubated on a rocker at room temperature for 1 h. Cells were washed three times with 
blocking buffer and then incubated with rocking at room temperature for 30 min with secondary 
antibodies diluted in blocking buffer. Finally, cells were washed twice with blocking buffer and once with 
PBS, and nuclei were stained with DAPI (4=,6-diamidino-2-phenylindole) diluted in PBS. Coverslips were 
mounted onto slides for analysis by confocal microscopy. NS4b was detected using anti-NS4b rabbit 
serum at 1:500 and NS4a with anti-NS4a rabbit serum at 1:500 (both obtained from Luis Enjuanes, 
Spanish National Centre for Biotechnology) (12). dsRNA was detected using commercial antibody J2 at 
1:1,000 and nsp8 using anti-nsp8 guinea pig serum (obtained from Mark Denison, Vanderbilt University). 
Secondary antibodies were all highly cross-adsorbed IgG (HL) from Invitrogen: goat-anti rabbit AF594 
(catalog no. AA11037), goat anti-mouse AF488 (catalog no. AA11029), goat anti-rabbit AF647 (catalog no. 
A32733), goat anti-guinea pig AF594 (catalog no. A11076), and goat anti-guinea pig AF568 (catalog no. 
A11075).
Western immunoblotting. Cells were washed twice with ice-cold PBS and lysates harvested at 
indicated times postinfection with lysis buffer (1% NP-40, 2 mM EDTA, 10% glycerol, 150 mM NaCl, 50 mM 
Tris HCl) supplemented with protease inhibitors (Roche cOmplete mini-EDTA-free protease inhibitor) and 
phosphatase inhibitors (Roche PhosStop Easy Pack). After 5 min, lysates were harvested, incubated on ice 
for 20 min, and centrifuged for 20 min at 4°C, and supernatants were mixed 3:1 with 4 Laemmli sample 
buffer. Samples were heated at 95°C for 5 min and then separated by 4 to 15% SDS-PAGE and transferred 
to polyvinylidene difluoride (PVDF) membranes. Blots were blocked with 5% nonfat milk and probed with 
the following antibodies diluted in the same blocking buffer: anti-PKR (phospho-T446 [E120]) rabbit 
monoclonal antibody (MAb) at 1:1,000 (Abcam 32036), anti-PKR (D7F7) rabbit MAb at 1:1,000 (Cell 
Signaling Technology no. 12297), anti-GAPDH (anti-glyceraldehyde-3-phosphate dehydrogenase [14C10]) 
rabbit MAb (Cell Signaling Technology no. 2118) at 1:1,000, SinoBiological anti-MERS N mouse MAb at 
1:1,000, anti-NS4a rabbit serum at 1:500 (obtained from Luis Enjuanes, Spanish National Centre for 
Biotechnology) (12), and anti-NS4b rabbit serum at 1:500 (obtained from Robert Silverman, Cleveland 
Clinic) (12). For detection of eIF2 and phosphorylated eIF2, blots were blocked with 5% BSA and 
probed with phospho-eIF2 (Ser51) antibody diluted in blocking buffer at 1:1,000 (Cell Signaling 
Technology no. 9721). The secondary antibodies used were horseradish peroxidase (HRP)-conjugated 
Santa Cruz goat anti-mouse IgG secondary antibody (SC2005) at 1:5,000 and HRP-linked Cell Signaling 
Technology anti-rabbit IgG secondary antibody (CS7074) at 1:3,000. Blots were visualized using Thermo 
Scientific SuperSignal West chemiluminescent substrates (catalog no. 34095 or 34080). Blots were probed 
sequentially with antibodies and between antibody treatments were stripped using Thermo Scientific 
Restore Western blot stripping buffer (catalog no. 21059).
Protein synthesis was assessed by treatment of cells with 10 g/ml puromycin for 10 min prior to 
protein harvest (35). Lysates were harvested and run on SDS-PAGE gels as described above. For detection 
of puromycin, antipuromycin mouse MAb (Millipore clone 4G11 MABE342) was used at 1:6,000, and the 
secondary antibody used was goat anti-mouse IgG-HRP (Thermo Scientific no. 31430) at 1:3,000. For 
detection of total protein by Coomassie staining, cell lysates (as prepared above) were separated by 4 to 
15% SDS-PAGE. Gels were fixed and stained with 0.05% Coomassie brilliant blue R250 (Bio-Rad no. 
161-0400) in 50% methanol–10% acetic acid solution for 2 h with gentle rocking at room temperature. 
Gels were destained with 7% methanol and 5% acetic acid for several hours and then imaged.
qRT-PCR. At indicated times postinfection, cells were lysed with buffer RLT Plus (Qiagen RNeasy Plus 
no. 74136) and RNA extracted following the prescribed protocol. cDNA was synthesized according to the 
protocol for Thermo Scientific Superscript III reverse transcriptase (Thermo Scientific no. 18080044). 
RT-qPCR was performed under conditions validated for the indicated primer set. The forward (F) and 
reverse (R) primer sequences are as follows: IFNL1, F, 5=-CGCCTTGGAAGAGTCACTCA-3=, and R, 5=-GAAG 
CCTCAGGTCCCAATTC-3=; OAS2, F, 5=-TTCTGCCTGCACCACTCTTCACGAC-3=, and R, 5=-GCCAGTCTTCAGAG 
CTGTGCCTTTG-3=; IFIT2, F, 5=-CTGAGAATTGCACTGCAACCATG-3=, and R, 5=-TCCCTCCATCAAGTTCCAGGT 
GAA-3=; IFNB, F, 5=-GTCAGAGTGGAAATCCTAAG-3=, and R, 5=-ACAGCATCTGCTGGTTGAAG-3=; and GAPDH, 
F, 5=-GCAAATTCCATGGCACCGT-3=, and R, 5=-TCGCCCCACTTGATTTTGG-3=. Fold changes in mRNA were 
calculated using the threshold cycle (CT) formula 2Δ(ΔCT) (ΔCT  CT gene of interest  CT GAPDH) and 
expressed as fold infected/mock infected.
Analyses of RNase L-mediated rRNA degradation. RNA was harvested with buffer RLT (Qiagen 
RNeasy no. 74106) and analyzed on an RNA chip with an Agilent Bioanalyzer using the Agilent RNA 6000 
Nano kit and its prescribed protocol, as we have described previously (catalog no. 5067-1511) (19, 23).
Statistical analysis. Plotting of data and statistical analysis were performed using GraphPad Prism 
software (GraphPad Software, Inc.). Statistical significance was determined by two-way analysis of 
variance (ANOVA) for viral replication curves and by unpaired Student’s t test for RT-qPCR.
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